专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006067063A2 SCREENING METHODS 审中-公开
标题翻译：筛选方法
公开(公告)号：WO2006067063A2
公开(公告)日：2006-06-29
申请号：PCT/EP2005/056694
申请日：2005-12-12
申请人： BIOVITRUM AB , PARROW, Vendela , BERGQUIST, Lars, Olof , DREIFELDT, Catrine , FLODIN, Christine
发明人： PARROW, Vendela , BERGQUIST, Lars, Olof , DREIFELDT, Catrine , FLODIN, Christine
IPC分类号： G01N33/50 , G01N33/74 , G01N33/68 , C07K14/71 , C07K14/61
CPC分类号： G01N33/5035 , G01N33/6863 , G01N33/74
摘要： The present invention relates to methods for the identification of modulators of cytokine class I receptors by determining whether a compound that binds to a cytokine class I receptor at a site different from the binding site of the naturally-occurring cytokine ligand is effective at modulating the amount of the cytokine class I receptor on the surface of the cell.
摘要翻译：本发明涉及通过确定在与天然存在的细胞因子配体的结合位点不同的位点结合细胞因子I类受体的化合物是否有效调节细胞因子I类受体的调节剂量的方法的细胞因子I受体在细胞表面。

2. 发明申请

WO2003087399A1 NAD)P)H OXIDASE INHIBITORS FOR INCREASED GLUCOSE UPTAKE AND TREATMENT OF TYPE II DIABETES 审中-公开
标题翻译： NAD）P）H氧化酶抑制剂用于增加葡萄糖摄取和治疗II型糖尿病
公开(公告)号：WO2003087399A1
公开(公告)日：2003-10-23
申请号：PCT/SE2003/000618
申请日：2003-04-16
申请人： BIOVITRUM AB , GRÖNBERG, Alvar , WIKSTRÖM, Per
发明人： GRÖNBERG, Alvar , WIKSTRÖM, Per
IPC分类号： C12Q1/26
CPC分类号： A61K31/255 , A61K31/03 , A61K31/12 , A61K31/265 , A61K31/305 , A61K31/4164 , A61K31/44 , C12Q1/26 , G01N33/66 , G01N33/6893 , G01N2500/04 , G01N2800/042 , Y10S514/866
摘要： The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.
摘要翻译：本发明涉及NAD（P）H氧化酶抑制剂用于增加葡萄糖的细胞摄取和用于治疗和/或预防由胰岛素抵抗或其相关疾病引起的疾病，例如II型糖尿病。具体地，本发明涉及用于鉴定可用于治疗或预防与血糖水平升高相关的医学病症的药剂的方法，所述方法包括（i）使候选药剂与哺乳动物NAD（P）H氧化酶或 NAD（P）H氧化酶复合物; 和（ii）确定所述候选试剂是否抑制NAD（P）H氧化酶或NAD（P）H氧化酶复合物的生物活性。

3. 发明申请

WO2003071264A1 CHROMATOGRAPHIC METHOD FOR DETERMINING THE MOLECULAR WEIGHT DISTRIBUTION OF AN ANIONIC POLYSACCHARIDE 审中-公开
标题翻译：用于测定阴离子多糖的分子量分布的色谱方法
公开(公告)号：WO2003071264A1
公开(公告)日：2003-08-28
申请号：PCT/SE2003/000274
申请日：2003-02-19
申请人： BIOVITRUM AB , KARLSSON, Göran
发明人： KARLSSON, Göran
IPC分类号： G01N30/02
CPC分类号： G01N30/96 , B01J41/20 , G01N30/02 , G01N33/44 , B01D15/363
摘要： Methods for determining the molecular weight distribution in a sample of an anionic polysaccharide is provided. The methods generally include: providing a sample of an anionic polysaccharide with an average molecular eight in the range of from 0.05 to 10 MDa; applying the sample to an anion-exchange chromatography column so as to immobilize the polysaccharide to the column; eluting the immobilized polysaccharide while recording a chromatogram of the amount of polysaccharide eluted as a function of time; and determining the molecular weight distribution in the polysaccharide sample through analysis of the chromatogram. Also provided is use of anion-exchange chromatography for the determination of molecular weight distribution in a sample of an anionic polysaccharide with an average molecular weight in the range of from 0.05 to 10 MDa.
摘要翻译：提供了确定阴离子多糖样品中分子量分布的方法。所述方法通常包括：提供平均分子量在0.05至10Mpa范围内的阴离子多糖样品; 将样品施加到阴离子交换色谱柱上，以将多糖固定在柱上; 洗脱固定的多糖，同时记录作为时间的函数洗脱的多糖的量的色谱图; 并通过分析色谱确定多糖样品中的分子量分布。还提供阴离子交换层析用于测定平均分子量为0.05至10Mpa的阴离子多糖样品中的分子量分布。

4. 发明申请

WO2004022592A1 USE OF HUMAN PROTEIN KINASE C-ETA IN METHODS FOR IDENTIFICATION OF PHARMACEUTICALLY USEFUL AGENTS 审中-公开
标题翻译：人体蛋白激酶C-ETA在药物有效试剂鉴定方法中的应用
公开(公告)号：WO2004022592A1
公开(公告)日：2004-03-18
申请号：PCT/SE2003/001361
申请日：2003-09-03
申请人： BIOVITRUM AB , ATTERSAND, Anneli , LAKE, Staffan
发明人： ATTERSAND, Anneli , LAKE, Staffan
IPC分类号： C07K14/47
CPC分类号： C12N9/1205
摘要： The invention relates to the use of the human Protein Kinase Cη (PKC-eta) isoform, in methods for identification of pharmaceutically useful agents, in particular agents useful for the treatment of type 2 diabetes.
摘要翻译：本发明涉及人类蛋白激酶Ceta（PKC-eta）同种型在用于鉴定药学上可用的试剂，特别是可用于治疗2型糖尿病的药剂的方法中的应用。

5. 发明申请

WO2003005025A1 METHODS FOR IDENTIFYING COMPOUNDS MODULATING THE ACTIVITY OF PPAR-GAMMA 审中-公开
标题翻译：鉴定调节PPAR-GAMMA活性的化合物的方法
公开(公告)号：WO2003005025A1
公开(公告)日：2003-01-16
申请号：PCT/SE2002/001322
申请日：2002-07-03
申请人： BIOVITRUM AB , GUSTAVSSON, Anna-Lena , SVENSSON, Stefan , UPPENBERG, Jonas
发明人： GUSTAVSSON, Anna-Lena , SVENSSON, Stefan , UPPENBERG, Jonas
IPC分类号： G01N33/50
CPC分类号： C07D213/30 , A61K31/00 , A61K31/33 , C07C233/81 , C07C275/30 , C07C311/17 , C07C323/12 , C07C323/20 , C07D209/08 , C07D213/643 , C07D213/65 , C07D213/70 , C07D213/71 , C07D213/74 , C07D215/14 , C07D233/84 , C07D233/91 , C07D239/34 , C07D239/52 , C07D241/18 , C07D241/44 , C07D263/32 , C07D277/24 , C07D307/42 , C07D307/54 , C07D307/81 , C07D317/60 , C07D333/16 , C07D333/18 , C07D333/24 , C07D333/28 , C07D333/60 , C07K2299/00 , G01N33/566 , G01N33/6803 , G01N2500/00
摘要： The present invention relates to a method for identifying compounds capable of binding the ligand binding domain of peroxisome proliferator-activated receptor gamma (PPARγ), and selectively modulating the activity of PPARγ. The said method includes providing compounds that fit spatially and preferentially into a PPARγ ligand binding domain. Said compounds comprise a) a benzoate group interacting with parts of Ile341, Cys285 and Gly284, b) a carboxylate group interacting with parts of Ser342 and c) an aromatic group interacting with parts of Leu330, Ile326, Arg288, Leu333 and Met329 of PPAR-gamma. Further claimed are pharmaceutical compositions for treating or preventing diabetes and a computer-readable data storage medium.
摘要翻译：本发明涉及鉴定能够结合过氧化物酶体增殖物激活受体γ（PPARγ）的配体结合域的化合物的方法，并且选择性调节PPARγ的活性。所述方法包括提供在空间上优先配入PPARγ配体结合域的化合物。所述化合物包含a）与Ile341，Cys285和Gly284的部分相互作用的苯甲酸酯基团，b）与Ser342部分相互作用的羧酸酯基团，和c）与PPAR-1的部分Leu330，Ile326，Arg288，Leu333和Met329相互作用的芳族基团，伽马。进一步要求保护的是用于治疗或预防糖尿病的药物组合物和计算机可读数据存储介质。

6. 发明申请

WO2002092804A1 METALLOPROTEASE M8 POLYNUCLEOTIDES AND POLYPEPTIDES AND SCREENING METHODS 审中-公开
标题翻译：金属多羟基化合物M8多核苷酸和多肽和筛选方法
公开(公告)号：WO2002092804A1
公开(公告)日：2002-11-21
申请号：PCT/SE2002/000931
申请日：2002-05-15
申请人： BIOVITRUM AB , DANIELSSON, Eva , HÖRLING, Jan , JANSSON, Magnus , JOHANSSON, Per , LAKE, Staffan , NILSSON, Joakim
发明人： DANIELSSON, Eva , HÖRLING, Jan , JANSSON, Magnus , JOHANSSON, Per , LAKE, Staffan , NILSSON, Joakim
IPC分类号： C12N9/64
CPC分类号： C12N9/6489 , A01K2217/05
摘要： The present invention relates to human metalloprotease M8 polypeptides and to nucleic acid molecules coding for such polypeptides. The invention further relates to vectors and cells comprising the nucleic acid molecules, as well as to methods for screening for test compounds which affect the insulin-signaling pathway.
摘要翻译：本发明涉及人金属蛋白酶M8多肽和编码这种多肽的核酸分子。本发明还涉及包含核酸分子的载体和细胞，以及用于筛选影响胰岛素信号传导途径的测试化合物的方法。

7. 发明申请

WO2002066669A1 METHOD FOR PURIFICATION OF SOLUBLE SSAO 审中-公开
标题翻译：纯化SSAO的方法
公开(公告)号：WO2002066669A1
公开(公告)日：2002-08-29
申请号：PCT/SE2002/000277
申请日：2002-02-18
申请人： BIOVITRUM AB , ABRAHMSÉN, Lars , NILSSON, Joakim
发明人： ABRAHMSÉN, Lars , NILSSON, Joakim
IPC分类号： C12P21/02
CPC分类号： C12N9/0022 , C07K2319/00 , C07K2319/02 , C07K2319/23 , C07K2319/50 , C12N15/62 , C12N15/625
摘要： The present invention relates to a recombinant construct comprising a nucleotide sequence encoding a fusion protein comprising a soluble form a human SSAO (Semicarbazide-Sensitive Amine Oxidase), a secretable fusion partner, a signal peptide; and a protease cleavage site. The said construct is useful in methods for purification of a soluble form of human SSAO.
摘要翻译：本发明涉及包含编码融合蛋白的核苷酸序列的重组构建体，所述融合蛋白包含可溶形式的人SSAO（氨基脲敏感性胺氧化酶），可分泌融合配偶体，信号肽; 和蛋白酶切割位点。所述构建体可用于纯化可溶形式的人SSAO的方法。

8. 发明申请

WO2012078101A1 METHOD FOR THE TREATMENT OF IL-1 MEDIATED DISEASES 审中-公开
标题翻译：治疗IL-1介导性疾病的方法
公开(公告)号：WO2012078101A1
公开(公告)日：2012-06-14
申请号：PCT/SE2011/051479
申请日：2011-12-06
申请人： SWEDISH ORPHAN BIOVITRUM AB (publ) , JAMES, Stephen
发明人： JAMES, Stephen
IPC分类号： A61K38/20 , A61P29/00
CPC分类号： A61K38/20 , A61K38/16
摘要： The present invention relates to methods for the treatment of IL-1 driven and autoinflammatory diseases by the continuous subcutaneous infusion of an IL-1 inhibitor, and more specifically, the IL-1 receptor antagonist (IL-1 ra) anakinra. The methods are useful in therapy, particularly for acute and chronic inflammatory diseases triggered by host-derived danger signals and for control of disease flares in recurring inflammatory syndromes.
摘要翻译：本发明涉及通过连续皮下输注IL-1抑制剂，更具体地说是IL-1受体拮抗剂（IL-1 ra）阿那金处理IL-1驱动和自身炎性疾病的方法。该方法在治疗中是有用的，特别是用于由宿主衍生的危险信号引发的急性和慢性炎性疾病以及用于控制复发性炎症综合征中疾病的发作。

9. 发明申请

WO2006122931A1 BETA-CARBOLINE DERIVATIVES AND THERI USE AS GHSR MODULATORS 审中-公开
标题翻译：测定碳氢化合物衍生物，并作为GHSR调节剂使用
公开(公告)号：WO2006122931A1
公开(公告)日：2006-11-23
申请号：PCT/EP2006/062343
申请日：2006-05-16
申请人： BIOVITRUM AB , GRAFFNER NORDBERG, Malin , BARF, Tjeerd , MOTT, Andrew
发明人： GRAFFNER NORDBERG, Malin , BARF, Tjeerd , MOTT, Andrew
IPC分类号： C07D471/20 , A61K31/438 , A61P3/04
CPC分类号： C07D471/20
摘要： The present invention relates to compounds of Formula (I): wherein R 1 to R 3 are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome Prader-Willi syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, intestinal inflammation that is associated with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, acromegaly and cancer, in particular breast, lung, prostate, thyroid and endocrine pituary carcinomas.
摘要翻译：本发明涉及式（I）化合物：其中R 1至R 3如本文所述，制备化合物的方法，包含该化合物的药物组合物和化合物和组合物在预防或治疗GHSR受体相关病症中的用途。这种障碍的实例是肥胖症和相关疾病，例如II型糖尿病，血脂异常和代谢综合征Prader-Willi综合征，心血管疾病如动脉粥样硬化性血管疾病，心绞痛，心肌梗塞和中风，与炎症性肠病相关的肠道炎症（IBD）如克罗恩病和溃疡性结肠炎，肢端肥大症和癌症，特别是乳腺癌，肺癌，前列腺癌，甲状腺和内分泌性胰腺癌。

10. 发明申请

WO2006067224A2 NEW COMPOUNDS 审中-公开
标题翻译：新化合物
公开(公告)号：WO2006067224A2
公开(公告)日：2006-06-29
申请号：PCT/EP2005/057132
申请日：2005-12-22
申请人： BIOVITRUM AB , BARKER, Emma , JENMALM JENSEN, Annika , NORDLING, Erik , PROUD, Andrew , SLATER, Martin , WEBER, Mikael
发明人： BARKER, Emma , JENMALM JENSEN, Annika , NORDLING, Erik , PROUD, Andrew , SLATER, Martin , WEBER, Mikael
CPC分类号： C07D491/10 , C07D493/10
摘要： The present invention relates to compounds of Formula (I): wherein R 1 , A, Y, n and m are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of orexin-1 receptor- related disorders and orexin-2 receptor-related disorders. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders.
摘要翻译：本发明涉及式（I）化合物：其中R 1，A，Y，n和m如本文所述，制备化合物的方法，包含该化合物的药物组合物，以及使用预防或治疗食欲肽-1受体相关疾病和食欲素-2受体相关疾病的化合物和组合物。这种障碍的实例是肥胖症和相关疾病，例如II型糖尿病，血脂异常和代谢综合征，心血管疾病如动脉粥样硬化性血管疾病，心绞痛，心肌梗死和中风，药物成瘾和睡眠障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式